nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Melphalan—breast cancer	0.391	1	CrCtD
L-DOPA—SLC7A5—Melphalan—breast cancer	0.175	0.915	CbGbCtD
L-DOPA—Melphalan—Chlorambucil—breast cancer	0.164	0.741	CrCrCtD
L-DOPA—CYP2D6—breast cancer	0.0529	1	CbGaD
L-DOPA—L-Tyrosine—Melphalan—breast cancer	0.0402	0.181	CrCrCtD
L-DOPA—L-Phenylalanine—Melphalan—breast cancer	0.0171	0.0769	CrCrCtD
L-DOPA—CYP2D6—Idarubicin—breast cancer	0.00676	0.0352	CbGbCtD
L-DOPA—CYP2D6—Vinorelbine—breast cancer	0.0033	0.0172	CbGbCtD
L-DOPA—CYP2D6—Tamoxifen—breast cancer	0.00298	0.0155	CbGbCtD
L-DOPA—CYP2D6—Vinblastine—breast cancer	0.00203	0.0106	CbGbCtD
L-DOPA—CYP2D6—Doxorubicin—breast cancer	0.00125	0.00651	CbGbCtD
L-DOPA—Mimosine—SHMT1—breast cancer	0.00114	0.508	CrCbGaD
L-DOPA—PSIP1—embryo—breast cancer	0.00105	0.0457	CbGeAlD
L-DOPA—SLC7A8—mammary gland—breast cancer	0.00102	0.0441	CbGeAlD
L-DOPA—SLC7A5—mammary gland—breast cancer	0.000789	0.0342	CbGeAlD
L-DOPA—PSIP1—endometrium—breast cancer	0.000771	0.0334	CbGeAlD
L-DOPA—PSIP1—Vinblastine—Vinorelbine—breast cancer	0.000762	0.727	CbGdCrCtD
L-DOPA—PSIP1—uterus—breast cancer	0.000711	0.0308	CbGeAlD
L-DOPA—PSIP1—pituitary gland—breast cancer	0.000698	0.0302	CbGeAlD
L-DOPA—PSIP1—adipose tissue—breast cancer	0.000695	0.0301	CbGeAlD
L-DOPA—SLC7A5—nipple—breast cancer	0.000652	0.0283	CbGeAlD
L-DOPA—PSIP1—female reproductive system—breast cancer	0.000639	0.0277	CbGeAlD
L-DOPA—PSIP1—adrenal gland—breast cancer	0.000623	0.027	CbGeAlD
L-DOPA—PSIP1—bone marrow—breast cancer	0.000603	0.0261	CbGeAlD
L-DOPA—DDC—embryo—breast cancer	0.000601	0.026	CbGeAlD
L-DOPA—PSIP1—female gonad—breast cancer	0.000581	0.0252	CbGeAlD
L-DOPA—PSIP1—endocrine gland—breast cancer	0.000541	0.0234	CbGeAlD
L-DOPA—SLC7A8—skin of body—breast cancer	0.000539	0.0234	CbGeAlD
L-DOPA—SLC16A10—nipple—breast cancer	0.000499	0.0216	CbGeAlD
L-DOPA—SLC7A8—pituitary gland—breast cancer	0.00046	0.0199	CbGeAlD
L-DOPA—SLC7A8—adipose tissue—breast cancer	0.000458	0.0198	CbGeAlD
L-DOPA—SLC7A5—epithelium—breast cancer	0.000439	0.019	CbGeAlD
L-DOPA—SLC7A8—female reproductive system—breast cancer	0.000421	0.0182	CbGeAlD
L-DOPA—SLC7A5—skin of body—breast cancer	0.000418	0.0181	CbGeAlD
L-DOPA—SLC7A8—adrenal gland—breast cancer	0.000411	0.0178	CbGeAlD
L-DOPA—SLC7A5—endometrium—breast cancer	0.000394	0.0171	CbGeAlD
L-DOPA—SLC7A8—female gonad—breast cancer	0.000383	0.0166	CbGeAlD
L-DOPA—PSIP1—lymph node—breast cancer	0.000374	0.0162	CbGeAlD
L-DOPA—SLC15A1—epithelium—breast cancer	0.000365	0.0158	CbGeAlD
L-DOPA—DDC—female reproductive system—breast cancer	0.000364	0.0158	CbGeAlD
L-DOPA—SLC7A5—uterus—breast cancer	0.000363	0.0157	CbGeAlD
L-DOPA—SLC7A5—pituitary gland—breast cancer	0.000356	0.0154	CbGeAlD
L-DOPA—SLC7A8—endocrine gland—breast cancer	0.000356	0.0154	CbGeAlD
L-DOPA—DDC—adrenal gland—breast cancer	0.000355	0.0154	CbGeAlD
L-DOPA—SLC7A5—adipose tissue—breast cancer	0.000355	0.0154	CbGeAlD
L-DOPA—DRD5—female reproductive system—breast cancer	0.00035	0.0152	CbGeAlD
L-DOPA—SLC16A10—epithelium—breast cancer	0.000336	0.0146	CbGeAlD
L-DOPA—SLC15A1—endometrium—breast cancer	0.000327	0.0142	CbGeAlD
L-DOPA—SLC7A5—female reproductive system—breast cancer	0.000326	0.0141	CbGeAlD
L-DOPA—DRD5—female gonad—breast cancer	0.000319	0.0138	CbGeAlD
L-DOPA—SLC7A5—adrenal gland—breast cancer	0.000318	0.0138	CbGeAlD
L-DOPA—DDC—endocrine gland—breast cancer	0.000308	0.0134	CbGeAlD
L-DOPA—SLC7A5—bone marrow—breast cancer	0.000308	0.0133	CbGeAlD
L-DOPA—SLC7A5—female gonad—breast cancer	0.000297	0.0129	CbGeAlD
L-DOPA—DRD5—endocrine gland—breast cancer	0.000296	0.0128	CbGeAlD
L-DOPA—SLC7A5—Desoximetasone—Fluoxymesterone—breast cancer	0.000286	0.273	CbGdCrCtD
L-DOPA—SLC7A5—endocrine gland—breast cancer	0.000276	0.012	CbGeAlD
L-DOPA—SLC16A10—adipose tissue—breast cancer	0.000272	0.0118	CbGeAlD
L-DOPA—Masoprocol—IGF1R—breast cancer	0.000254	0.113	CrCbGaD
L-DOPA—SLC16A10—female reproductive system—breast cancer	0.00025	0.0108	CbGeAlD
L-DOPA—SLC7A8—lymph node—breast cancer	0.000246	0.0107	CbGeAlD
L-DOPA—SLC15A1—endocrine gland—breast cancer	0.000229	0.00993	CbGeAlD
L-DOPA—DDC—lymph node—breast cancer	0.000213	0.00923	CbGeAlD
L-DOPA—SLC16A10—endocrine gland—breast cancer	0.000211	0.00916	CbGeAlD
L-DOPA—SLC7A5—lymph node—breast cancer	0.000191	0.00827	CbGeAlD
L-DOPA—Liothyronine—THRB—breast cancer	0.000186	0.0828	CrCbGaD
L-DOPA—DRD2—pituitary gland—breast cancer	0.000173	0.00749	CbGeAlD
L-DOPA—SLC16A10—lymph node—breast cancer	0.000146	0.00633	CbGeAlD
L-DOPA—DRD2—endocrine gland—breast cancer	0.000134	0.0058	CbGeAlD
L-DOPA—Methyldopa—COMT—breast cancer	0.000113	0.0506	CrCbGaD
L-DOPA—Liothyronine—SLCO1B1—breast cancer	0.000109	0.0485	CrCbGaD
L-DOPA—CYP2D6—female reproductive system—breast cancer	9.5e-05	0.00412	CbGeAlD
L-DOPA—CYP2D6—female gonad—breast cancer	8.65e-05	0.00375	CbGeAlD
L-DOPA—CYP2D6—endocrine gland—breast cancer	8.04e-05	0.00348	CbGeAlD
L-DOPA—Masoprocol—CYP19A1—breast cancer	8.03e-05	0.0358	CrCbGaD
L-DOPA—Aminosalicylic Acid—PTGS1—breast cancer	6.01e-05	0.0268	CrCbGaD
L-DOPA—Dopamine—COMT—breast cancer	5.54e-05	0.0247	CrCbGaD
L-DOPA—Mesalazine—PTGS1—breast cancer	4.71e-05	0.021	CrCbGaD
L-DOPA—Aminosalicylic Acid—PTGS2—breast cancer	3.43e-05	0.0153	CrCbGaD
L-DOPA—Epinephrine—TNF—breast cancer	3.27e-05	0.0146	CrCbGaD
L-DOPA—Isoprenaline—CYP1A1—breast cancer	2.95e-05	0.0132	CrCbGaD
L-DOPA—Mesalazine—PTGS2—breast cancer	2.69e-05	0.012	CrCbGaD
L-DOPA—Liothyronine—ALB—breast cancer	2.07e-05	0.00921	CrCbGaD
L-DOPA—Liothyronine—ABCB1—breast cancer	1.97e-05	0.00879	CrCbGaD
L-DOPA—Dopamine—CYP2D6—breast cancer	1.89e-05	0.00844	CrCbGaD
L-DOPA—Diarrhoea—Fluorouracil—breast cancer	1.87e-05	0.000243	CcSEcCtD
L-DOPA—Thrombocytopenia—Capecitabine—breast cancer	1.87e-05	0.000243	CcSEcCtD
L-DOPA—Hypoaesthesia—Epirubicin—breast cancer	1.86e-05	0.000242	CcSEcCtD
L-DOPA—Urinary tract disorder—Epirubicin—breast cancer	1.85e-05	0.000241	CcSEcCtD
L-DOPA—Urticaria—Paclitaxel—breast cancer	1.85e-05	0.00024	CcSEcCtD
L-DOPA—Hyperhidrosis—Capecitabine—breast cancer	1.84e-05	0.00024	CcSEcCtD
L-DOPA—Hypotension—Docetaxel—breast cancer	1.84e-05	0.00024	CcSEcCtD
L-DOPA—Abdominal pain—Paclitaxel—breast cancer	1.84e-05	0.000239	CcSEcCtD
L-DOPA—Urethral disorder—Epirubicin—breast cancer	1.83e-05	0.000239	CcSEcCtD
L-DOPA—Anorexia—Capecitabine—breast cancer	1.82e-05	0.000237	CcSEcCtD
L-DOPA—Vomiting—Mitoxantrone—breast cancer	1.81e-05	0.000236	CcSEcCtD
L-DOPA—Vomiting—Irinotecan—breast cancer	1.81e-05	0.000236	CcSEcCtD
L-DOPA—Dizziness—Fluorouracil—breast cancer	1.8e-05	0.000235	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—breast cancer	1.8e-05	0.000234	CcSEcCtD
L-DOPA—Rash—Mitoxantrone—breast cancer	1.8e-05	0.000234	CcSEcCtD
L-DOPA—Rash—Irinotecan—breast cancer	1.8e-05	0.000234	CcSEcCtD
L-DOPA—Dermatitis—Irinotecan—breast cancer	1.8e-05	0.000234	CcSEcCtD
L-DOPA—Dermatitis—Mitoxantrone—breast cancer	1.8e-05	0.000234	CcSEcCtD
L-DOPA—Headache—Mitoxantrone—breast cancer	1.79e-05	0.000233	CcSEcCtD
L-DOPA—Headache—Irinotecan—breast cancer	1.79e-05	0.000233	CcSEcCtD
L-DOPA—Hypotension—Capecitabine—breast cancer	1.78e-05	0.000232	CcSEcCtD
L-DOPA—Insomnia—Docetaxel—breast cancer	1.78e-05	0.000232	CcSEcCtD
L-DOPA—Paraesthesia—Docetaxel—breast cancer	1.77e-05	0.00023	CcSEcCtD
L-DOPA—Alopecia—Methotrexate—breast cancer	1.77e-05	0.00023	CcSEcCtD
L-DOPA—Vomiting—Gemcitabine—breast cancer	1.77e-05	0.00023	CcSEcCtD
L-DOPA—Dyspnoea—Docetaxel—breast cancer	1.76e-05	0.000229	CcSEcCtD
L-DOPA—Somnolence—Docetaxel—breast cancer	1.75e-05	0.000228	CcSEcCtD
L-DOPA—Mental disorder—Methotrexate—breast cancer	1.75e-05	0.000228	CcSEcCtD
L-DOPA—Rash—Gemcitabine—breast cancer	1.75e-05	0.000228	CcSEcCtD
L-DOPA—Dermatitis—Gemcitabine—breast cancer	1.75e-05	0.000228	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—breast cancer	1.74e-05	0.000227	CcSEcCtD
L-DOPA—Headache—Gemcitabine—breast cancer	1.74e-05	0.000226	CcSEcCtD
L-DOPA—Flushing—Epirubicin—breast cancer	1.74e-05	0.000226	CcSEcCtD
L-DOPA—Vomiting—Fluorouracil—breast cancer	1.74e-05	0.000226	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—breast cancer	1.73e-05	0.000226	CcSEcCtD
L-DOPA—Dyspepsia—Docetaxel—breast cancer	1.73e-05	0.000226	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—breast cancer	1.73e-05	0.000225	CcSEcCtD
L-DOPA—Insomnia—Capecitabine—breast cancer	1.73e-05	0.000225	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—breast cancer	1.72e-05	0.000224	CcSEcCtD
L-DOPA—Rash—Fluorouracil—breast cancer	1.72e-05	0.000224	CcSEcCtD
L-DOPA—Dermatitis—Fluorouracil—breast cancer	1.72e-05	0.000224	CcSEcCtD
L-DOPA—Paraesthesia—Capecitabine—breast cancer	1.71e-05	0.000223	CcSEcCtD
L-DOPA—Decreased appetite—Docetaxel—breast cancer	1.71e-05	0.000223	CcSEcCtD
L-DOPA—Hypersensitivity—Paclitaxel—breast cancer	1.71e-05	0.000223	CcSEcCtD
L-DOPA—Headache—Fluorouracil—breast cancer	1.71e-05	0.000223	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—breast cancer	1.71e-05	0.000223	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—breast cancer	1.7e-05	0.000222	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Docetaxel—breast cancer	1.7e-05	0.000221	CcSEcCtD
L-DOPA—Dyspnoea—Capecitabine—breast cancer	1.7e-05	0.000221	CcSEcCtD
L-DOPA—Fatigue—Docetaxel—breast cancer	1.7e-05	0.000221	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—breast cancer	1.7e-05	0.000221	CcSEcCtD
L-DOPA—Nausea—Irinotecan—breast cancer	1.69e-05	0.00022	CcSEcCtD
L-DOPA—Nausea—Mitoxantrone—breast cancer	1.69e-05	0.00022	CcSEcCtD
L-DOPA—Constipation—Docetaxel—breast cancer	1.68e-05	0.000219	CcSEcCtD
L-DOPA—Pain—Docetaxel—breast cancer	1.68e-05	0.000219	CcSEcCtD
L-DOPA—Back pain—Methotrexate—breast cancer	1.68e-05	0.000219	CcSEcCtD
L-DOPA—Dyspepsia—Capecitabine—breast cancer	1.68e-05	0.000219	CcSEcCtD
L-DOPA—Arrhythmia—Epirubicin—breast cancer	1.67e-05	0.000218	CcSEcCtD
L-DOPA—Asthenia—Paclitaxel—breast cancer	1.67e-05	0.000217	CcSEcCtD
L-DOPA—Decreased appetite—Capecitabine—breast cancer	1.66e-05	0.000216	CcSEcCtD
L-DOPA—Alopecia—Epirubicin—breast cancer	1.65e-05	0.000215	CcSEcCtD
L-DOPA—Nausea—Gemcitabine—breast cancer	1.65e-05	0.000215	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Capecitabine—breast cancer	1.65e-05	0.000214	CcSEcCtD
L-DOPA—Fatigue—Capecitabine—breast cancer	1.64e-05	0.000214	CcSEcCtD
L-DOPA—Pruritus—Paclitaxel—breast cancer	1.64e-05	0.000214	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—breast cancer	1.64e-05	0.000214	CcSEcCtD
L-DOPA—Mental disorder—Epirubicin—breast cancer	1.64e-05	0.000213	CcSEcCtD
L-DOPA—Pain—Capecitabine—breast cancer	1.63e-05	0.000212	CcSEcCtD
L-DOPA—Constipation—Capecitabine—breast cancer	1.63e-05	0.000212	CcSEcCtD
L-DOPA—Feeling abnormal—Docetaxel—breast cancer	1.62e-05	0.000211	CcSEcCtD
L-DOPA—Nausea—Fluorouracil—breast cancer	1.62e-05	0.000211	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—breast cancer	1.61e-05	0.00021	CcSEcCtD
L-DOPA—Gastrointestinal pain—Docetaxel—breast cancer	1.61e-05	0.00021	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—breast cancer	1.61e-05	0.000209	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—breast cancer	1.61e-05	0.000209	CcSEcCtD
L-DOPA—Flatulence—Epirubicin—breast cancer	1.6e-05	0.000209	CcSEcCtD
L-DOPA—Tension—Epirubicin—breast cancer	1.6e-05	0.000208	CcSEcCtD
L-DOPA—Dysgeusia—Epirubicin—breast cancer	1.59e-05	0.000208	CcSEcCtD
L-DOPA—Diarrhoea—Paclitaxel—breast cancer	1.59e-05	0.000207	CcSEcCtD
L-DOPA—Epinephrine—CYP3A4—breast cancer	1.58e-05	0.00706	CrCbGaD
L-DOPA—Nervousness—Epirubicin—breast cancer	1.58e-05	0.000206	CcSEcCtD
L-DOPA—Back pain—Epirubicin—breast cancer	1.57e-05	0.000205	CcSEcCtD
L-DOPA—Feeling abnormal—Capecitabine—breast cancer	1.57e-05	0.000205	CcSEcCtD
L-DOPA—Malaise—Methotrexate—breast cancer	1.57e-05	0.000204	CcSEcCtD
L-DOPA—Muscle spasms—Epirubicin—breast cancer	1.57e-05	0.000204	CcSEcCtD
L-DOPA—Gastrointestinal pain—Capecitabine—breast cancer	1.56e-05	0.000203	CcSEcCtD
L-DOPA—Abdominal pain—Docetaxel—breast cancer	1.56e-05	0.000203	CcSEcCtD
L-DOPA—Leukopenia—Methotrexate—breast cancer	1.56e-05	0.000203	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—breast cancer	1.55e-05	0.000201	CcSEcCtD
L-DOPA—Dizziness—Paclitaxel—breast cancer	1.54e-05	0.0002	CcSEcCtD
L-DOPA—Vision blurred—Epirubicin—breast cancer	1.53e-05	0.0002	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—breast cancer	1.53e-05	0.000199	CcSEcCtD
L-DOPA—Cough—Methotrexate—breast cancer	1.52e-05	0.000198	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—breast cancer	1.52e-05	0.000197	CcSEcCtD
L-DOPA—Urticaria—Capecitabine—breast cancer	1.52e-05	0.000197	CcSEcCtD
L-DOPA—Ill-defined disorder—Epirubicin—breast cancer	1.51e-05	0.000197	CcSEcCtD
L-DOPA—Abdominal pain—Capecitabine—breast cancer	1.51e-05	0.000196	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—breast cancer	1.51e-05	0.000196	CcSEcCtD
L-DOPA—Anaemia—Epirubicin—breast cancer	1.5e-05	0.000196	CcSEcCtD
L-DOPA—Agitation—Epirubicin—breast cancer	1.5e-05	0.000195	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—breast cancer	1.48e-05	0.000193	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—breast cancer	1.48e-05	0.000193	CcSEcCtD
L-DOPA—Tension—Doxorubicin—breast cancer	1.48e-05	0.000193	CcSEcCtD
L-DOPA—Vomiting—Paclitaxel—breast cancer	1.48e-05	0.000192	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—breast cancer	1.48e-05	0.000192	CcSEcCtD
L-DOPA—Malaise—Epirubicin—breast cancer	1.47e-05	0.000191	CcSEcCtD
L-DOPA—Rash—Paclitaxel—breast cancer	1.47e-05	0.000191	CcSEcCtD
L-DOPA—Dermatitis—Paclitaxel—breast cancer	1.46e-05	0.000191	CcSEcCtD
L-DOPA—Discomfort—Methotrexate—breast cancer	1.46e-05	0.000191	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—breast cancer	1.46e-05	0.000191	CcSEcCtD
L-DOPA—Syncope—Epirubicin—breast cancer	1.46e-05	0.00019	CcSEcCtD
L-DOPA—Leukopenia—Epirubicin—breast cancer	1.46e-05	0.00019	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—breast cancer	1.46e-05	0.00019	CcSEcCtD
L-DOPA—Headache—Paclitaxel—breast cancer	1.46e-05	0.00019	CcSEcCtD
L-DOPA—Hypersensitivity—Docetaxel—breast cancer	1.45e-05	0.000189	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—breast cancer	1.45e-05	0.000189	CcSEcCtD
L-DOPA—Palpitations—Epirubicin—breast cancer	1.44e-05	0.000187	CcSEcCtD
L-DOPA—Confusional state—Methotrexate—breast cancer	1.43e-05	0.000186	CcSEcCtD
L-DOPA—Loss of consciousness—Epirubicin—breast cancer	1.43e-05	0.000186	CcSEcCtD
L-DOPA—Cough—Epirubicin—breast cancer	1.42e-05	0.000185	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—breast cancer	1.42e-05	0.000185	CcSEcCtD
L-DOPA—Asthenia—Docetaxel—breast cancer	1.41e-05	0.000184	CcSEcCtD
L-DOPA—Convulsion—Epirubicin—breast cancer	1.41e-05	0.000184	CcSEcCtD
L-DOPA—Hypertension—Epirubicin—breast cancer	1.41e-05	0.000183	CcSEcCtD
L-DOPA—Hypersensitivity—Capecitabine—breast cancer	1.41e-05	0.000183	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—breast cancer	1.4e-05	0.000182	CcSEcCtD
L-DOPA—Pruritus—Docetaxel—breast cancer	1.39e-05	0.000182	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—breast cancer	1.39e-05	0.000181	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—breast cancer	1.39e-05	0.000181	CcSEcCtD
L-DOPA—Chest pain—Epirubicin—breast cancer	1.39e-05	0.000181	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—breast cancer	1.38e-05	0.00018	CcSEcCtD
L-DOPA—Anxiety—Epirubicin—breast cancer	1.38e-05	0.00018	CcSEcCtD
L-DOPA—Nausea—Paclitaxel—breast cancer	1.38e-05	0.00018	CcSEcCtD
L-DOPA—Hyperhidrosis—Methotrexate—breast cancer	1.37e-05	0.000179	CcSEcCtD
L-DOPA—Discomfort—Epirubicin—breast cancer	1.37e-05	0.000178	CcSEcCtD
L-DOPA—Asthenia—Capecitabine—breast cancer	1.37e-05	0.000178	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—breast cancer	1.36e-05	0.000177	CcSEcCtD
L-DOPA—Dry mouth—Epirubicin—breast cancer	1.36e-05	0.000177	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—breast cancer	1.35e-05	0.000176	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—breast cancer	1.35e-05	0.000176	CcSEcCtD
L-DOPA—Pruritus—Capecitabine—breast cancer	1.35e-05	0.000176	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—breast cancer	1.35e-05	0.000176	CcSEcCtD
L-DOPA—Diarrhoea—Docetaxel—breast cancer	1.35e-05	0.000176	CcSEcCtD
L-DOPA—Confusional state—Epirubicin—breast cancer	1.34e-05	0.000174	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—breast cancer	1.33e-05	0.000173	CcSEcCtD
L-DOPA—Oedema—Epirubicin—breast cancer	1.33e-05	0.000173	CcSEcCtD
L-DOPA—Hypotension—Methotrexate—breast cancer	1.33e-05	0.000173	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—breast cancer	1.32e-05	0.000172	CcSEcCtD
L-DOPA—Cough—Doxorubicin—breast cancer	1.31e-05	0.000171	CcSEcCtD
L-DOPA—Shock—Epirubicin—breast cancer	1.31e-05	0.00017	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—breast cancer	1.31e-05	0.00017	CcSEcCtD
L-DOPA—Diarrhoea—Capecitabine—breast cancer	1.3e-05	0.00017	CcSEcCtD
L-DOPA—Dizziness—Docetaxel—breast cancer	1.3e-05	0.00017	CcSEcCtD
L-DOPA—Thrombocytopenia—Epirubicin—breast cancer	1.3e-05	0.000169	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—breast cancer	1.3e-05	0.000169	CcSEcCtD
L-DOPA—Hyperhidrosis—Epirubicin—breast cancer	1.28e-05	0.000167	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—breast cancer	1.28e-05	0.000167	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—breast cancer	1.28e-05	0.000167	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—breast cancer	1.28e-05	0.000166	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—breast cancer	1.27e-05	0.000166	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—breast cancer	1.27e-05	0.000165	CcSEcCtD
L-DOPA—Anorexia—Epirubicin—breast cancer	1.27e-05	0.000165	CcSEcCtD
L-DOPA—Dyspnoea—Methotrexate—breast cancer	1.27e-05	0.000165	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—breast cancer	1.26e-05	0.000164	CcSEcCtD
L-DOPA—Dizziness—Capecitabine—breast cancer	1.26e-05	0.000164	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—breast cancer	1.25e-05	0.000163	CcSEcCtD
L-DOPA—Vomiting—Docetaxel—breast cancer	1.25e-05	0.000163	CcSEcCtD
L-DOPA—Dyspepsia—Methotrexate—breast cancer	1.25e-05	0.000163	CcSEcCtD
L-DOPA—Rash—Docetaxel—breast cancer	1.24e-05	0.000162	CcSEcCtD
L-DOPA—Hypotension—Epirubicin—breast cancer	1.24e-05	0.000162	CcSEcCtD
L-DOPA—Dermatitis—Docetaxel—breast cancer	1.24e-05	0.000162	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—breast cancer	1.24e-05	0.000161	CcSEcCtD
L-DOPA—Decreased appetite—Methotrexate—breast cancer	1.23e-05	0.000161	CcSEcCtD
L-DOPA—Headache—Docetaxel—breast cancer	1.23e-05	0.000161	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—breast cancer	1.23e-05	0.00016	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Methotrexate—breast cancer	1.23e-05	0.00016	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—breast cancer	1.22e-05	0.000159	CcSEcCtD
L-DOPA—Pain—Methotrexate—breast cancer	1.21e-05	0.000158	CcSEcCtD
L-DOPA—Vomiting—Capecitabine—breast cancer	1.21e-05	0.000158	CcSEcCtD
L-DOPA—Shock—Doxorubicin—breast cancer	1.21e-05	0.000158	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—breast cancer	1.2e-05	0.000157	CcSEcCtD
L-DOPA—Rash—Capecitabine—breast cancer	1.2e-05	0.000157	CcSEcCtD
L-DOPA—Insomnia—Epirubicin—breast cancer	1.2e-05	0.000157	CcSEcCtD
L-DOPA—Dermatitis—Capecitabine—breast cancer	1.2e-05	0.000156	CcSEcCtD
L-DOPA—Headache—Capecitabine—breast cancer	1.19e-05	0.000156	CcSEcCtD
L-DOPA—Paraesthesia—Epirubicin—breast cancer	1.19e-05	0.000155	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—breast cancer	1.19e-05	0.000155	CcSEcCtD
L-DOPA—Dyspnoea—Epirubicin—breast cancer	1.18e-05	0.000154	CcSEcCtD
L-DOPA—Somnolence—Epirubicin—breast cancer	1.18e-05	0.000154	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—breast cancer	1.17e-05	0.000153	CcSEcCtD
L-DOPA—Nausea—Docetaxel—breast cancer	1.17e-05	0.000152	CcSEcCtD
L-DOPA—Feeling abnormal—Methotrexate—breast cancer	1.17e-05	0.000152	CcSEcCtD
L-DOPA—Dyspepsia—Epirubicin—breast cancer	1.17e-05	0.000152	CcSEcCtD
L-DOPA—Gastrointestinal pain—Methotrexate—breast cancer	1.16e-05	0.000151	CcSEcCtD
L-DOPA—Decreased appetite—Epirubicin—breast cancer	1.16e-05	0.00015	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—breast cancer	1.15e-05	0.00015	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Epirubicin—breast cancer	1.15e-05	0.000149	CcSEcCtD
L-DOPA—Fatigue—Epirubicin—breast cancer	1.15e-05	0.000149	CcSEcCtD
L-DOPA—Pain—Epirubicin—breast cancer	1.14e-05	0.000148	CcSEcCtD
L-DOPA—Constipation—Epirubicin—breast cancer	1.14e-05	0.000148	CcSEcCtD
L-DOPA—Nausea—Capecitabine—breast cancer	1.13e-05	0.000148	CcSEcCtD
L-DOPA—Urticaria—Methotrexate—breast cancer	1.13e-05	0.000147	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—breast cancer	1.12e-05	0.000146	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—breast cancer	1.11e-05	0.000145	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—breast cancer	1.1e-05	0.000144	CcSEcCtD
L-DOPA—Dyspnoea—Doxorubicin—breast cancer	1.1e-05	0.000143	CcSEcCtD
L-DOPA—Feeling abnormal—Epirubicin—breast cancer	1.09e-05	0.000143	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—breast cancer	1.09e-05	0.000142	CcSEcCtD
L-DOPA—Gastrointestinal pain—Epirubicin—breast cancer	1.09e-05	0.000142	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—breast cancer	1.08e-05	0.000141	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—breast cancer	1.07e-05	0.000139	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—breast cancer	1.06e-05	0.000138	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—breast cancer	1.06e-05	0.000138	CcSEcCtD
L-DOPA—Urticaria—Epirubicin—breast cancer	1.06e-05	0.000137	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—breast cancer	1.05e-05	0.000137	CcSEcCtD
L-DOPA—Pain—Doxorubicin—breast cancer	1.05e-05	0.000137	CcSEcCtD
L-DOPA—Abdominal pain—Epirubicin—breast cancer	1.05e-05	0.000137	CcSEcCtD
L-DOPA—Hypersensitivity—Methotrexate—breast cancer	1.05e-05	0.000136	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—breast cancer	1.02e-05	0.000133	CcSEcCtD
L-DOPA—Feeling abnormal—Doxorubicin—breast cancer	1.01e-05	0.000132	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—breast cancer	1.01e-05	0.000131	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—breast cancer	1e-05	0.000131	CcSEcCtD
L-DOPA—Hypersensitivity—Epirubicin—breast cancer	9.79e-06	0.000127	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—breast cancer	9.77e-06	0.000127	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—breast cancer	9.72e-06	0.000127	CcSEcCtD
L-DOPA—Diarrhoea—Methotrexate—breast cancer	9.71e-06	0.000127	CcSEcCtD
L-DOPA—Asthenia—Epirubicin—breast cancer	9.53e-06	0.000124	CcSEcCtD
L-DOPA—Pruritus—Epirubicin—breast cancer	9.4e-06	0.000122	CcSEcCtD
L-DOPA—Dizziness—Methotrexate—breast cancer	9.39e-06	0.000122	CcSEcCtD
L-DOPA—Diarrhoea—Epirubicin—breast cancer	9.09e-06	0.000118	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—breast cancer	9.06e-06	0.000118	CcSEcCtD
L-DOPA—Vomiting—Methotrexate—breast cancer	9.03e-06	0.000118	CcSEcCtD
L-DOPA—Rash—Methotrexate—breast cancer	8.95e-06	0.000117	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—breast cancer	8.94e-06	0.000116	CcSEcCtD
L-DOPA—Headache—Methotrexate—breast cancer	8.89e-06	0.000116	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—breast cancer	8.82e-06	0.000115	CcSEcCtD
L-DOPA—Dizziness—Epirubicin—breast cancer	8.79e-06	0.000114	CcSEcCtD
L-DOPA—Pruritus—Doxorubicin—breast cancer	8.7e-06	0.000113	CcSEcCtD
L-DOPA—Vomiting—Epirubicin—breast cancer	8.45e-06	0.00011	CcSEcCtD
L-DOPA—Nausea—Methotrexate—breast cancer	8.43e-06	0.00011	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—breast cancer	8.41e-06	0.00011	CcSEcCtD
L-DOPA—Rash—Epirubicin—breast cancer	8.38e-06	0.000109	CcSEcCtD
L-DOPA—Dermatitis—Epirubicin—breast cancer	8.37e-06	0.000109	CcSEcCtD
L-DOPA—Headache—Epirubicin—breast cancer	8.32e-06	0.000108	CcSEcCtD
L-DOPA—Dizziness—Doxorubicin—breast cancer	8.13e-06	0.000106	CcSEcCtD
L-DOPA—Nausea—Epirubicin—breast cancer	7.89e-06	0.000103	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—breast cancer	7.82e-06	0.000102	CcSEcCtD
L-DOPA—Rash—Doxorubicin—breast cancer	7.75e-06	0.000101	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—breast cancer	7.74e-06	0.000101	CcSEcCtD
L-DOPA—Headache—Doxorubicin—breast cancer	7.7e-06	0.0001	CcSEcCtD
L-DOPA—Nausea—Doxorubicin—breast cancer	7.3e-06	9.51e-05	CcSEcCtD
L-DOPA—DRD3—Signaling Pathways—KIT—breast cancer	1.57e-06	4e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CG—breast cancer	1.57e-06	4e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APC—breast cancer	1.57e-06	4e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—E2F1—breast cancer	1.57e-06	3.99e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CB—breast cancer	1.56e-06	3.97e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CD—breast cancer	1.56e-06	3.96e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGF—breast cancer	1.56e-06	3.95e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK8—breast cancer	1.56e-06	3.95e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—FASN—breast cancer	1.55e-06	3.95e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—breast cancer	1.55e-06	3.94e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—BCHE—breast cancer	1.55e-06	3.93e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CA—breast cancer	1.54e-06	3.92e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SERPINE1—breast cancer	1.54e-06	3.92e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC5A5—breast cancer	1.53e-06	3.89e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—MAPK3—breast cancer	1.53e-06	3.88e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—breast cancer	1.53e-06	3.88e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SPP1—breast cancer	1.51e-06	3.83e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—MAPK3—breast cancer	1.51e-06	3.83e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—breast cancer	1.5e-06	3.82e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—BRAF—breast cancer	1.5e-06	3.81e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB3—breast cancer	1.49e-06	3.79e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGFR2—breast cancer	1.49e-06	3.79e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—BRAF—breast cancer	1.48e-06	3.76e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC2A1—breast cancer	1.48e-06	3.75e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NQO1—breast cancer	1.48e-06	3.75e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SRC—breast cancer	1.47e-06	3.75e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOS3—breast cancer	1.47e-06	3.74e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1—breast cancer	1.46e-06	3.71e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT2—breast cancer	1.46e-06	3.71e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—breast cancer	1.45e-06	3.69e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1—breast cancer	1.44e-06	3.66e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT2—breast cancer	1.44e-06	3.66e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP3A4—breast cancer	1.44e-06	3.66e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—breast cancer	1.44e-06	3.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2—breast cancer	1.44e-06	3.65e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—breast cancer	1.43e-06	3.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TERT—breast cancer	1.43e-06	3.63e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STAT3—breast cancer	1.42e-06	3.61e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP1B1—breast cancer	1.42e-06	3.6e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CD—breast cancer	1.4e-06	3.56e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CA—breast cancer	1.4e-06	3.56e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MDM2—breast cancer	1.4e-06	3.55e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—breast cancer	1.39e-06	3.54e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RAF1—breast cancer	1.39e-06	3.54e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CA—breast cancer	1.39e-06	3.53e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HSP90AA1—breast cancer	1.39e-06	3.53e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGFR1—breast cancer	1.39e-06	3.53e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SERPINE1—breast cancer	1.39e-06	3.53e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RELA—breast cancer	1.39e-06	3.52e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CD—breast cancer	1.38e-06	3.52e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB2—breast cancer	1.38e-06	3.5e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—breast cancer	1.37e-06	3.49e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CA—breast cancer	1.37e-06	3.48e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SERPINE1—breast cancer	1.37e-06	3.48e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HIF1A—breast cancer	1.37e-06	3.48e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK3—breast cancer	1.36e-06	3.45e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MTOR—breast cancer	1.36e-06	3.45e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CB—breast cancer	1.36e-06	3.45e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—breast cancer	1.36e-06	3.44e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NCOA1—breast cancer	1.35e-06	3.43e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LEP—breast cancer	1.34e-06	3.39e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—STK11—breast cancer	1.33e-06	3.38e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP19A1—breast cancer	1.33e-06	3.38e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOS3—breast cancer	1.32e-06	3.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CAV1—breast cancer	1.32e-06	3.36e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—breast cancer	1.32e-06	3.36e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TGFB1—breast cancer	1.32e-06	3.35e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KDR—breast cancer	1.31e-06	3.32e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOS3—breast cancer	1.31e-06	3.32e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—breast cancer	1.31e-06	3.32e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HRAS—breast cancer	1.3e-06	3.3e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—breast cancer	1.29e-06	3.28e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1B—breast cancer	1.27e-06	3.24e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ESR1—breast cancer	1.27e-06	3.24e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CA—breast cancer	1.26e-06	3.21e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—breast cancer	1.26e-06	3.2e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FN1—breast cancer	1.26e-06	3.2e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MDM2—breast cancer	1.26e-06	3.19e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RAF1—breast cancer	1.25e-06	3.18e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP3—breast cancer	1.25e-06	3.17e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2—breast cancer	1.25e-06	3.17e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RELA—breast cancer	1.25e-06	3.17e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CA—breast cancer	1.25e-06	3.16e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NFKBIA—breast cancer	1.24e-06	3.16e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—breast cancer	1.24e-06	3.15e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MDM2—breast cancer	1.24e-06	3.15e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB2—breast cancer	1.24e-06	3.15e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—COMT—breast cancer	1.24e-06	3.14e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RAF1—breast cancer	1.24e-06	3.14e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOTCH1—breast cancer	1.23e-06	3.13e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTP1—breast cancer	1.23e-06	3.13e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RELA—breast cancer	1.23e-06	3.13e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MTOR—breast cancer	1.22e-06	3.11e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CB—breast cancer	1.22e-06	3.11e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB2—breast cancer	1.22e-06	3.11e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—breast cancer	1.22e-06	3.1e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—breast cancer	1.22e-06	3.09e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HMOX1—breast cancer	1.21e-06	3.09e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JUN—breast cancer	1.21e-06	3.08e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ITPR1—breast cancer	1.21e-06	3.08e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MTOR—breast cancer	1.21e-06	3.07e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CB—breast cancer	1.21e-06	3.07e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KIT—breast cancer	1.2e-06	3.06e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APC—breast cancer	1.2e-06	3.06e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CG—breast cancer	1.2e-06	3.06e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CTNNB1—breast cancer	1.2e-06	3.06e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGF—breast cancer	1.19e-06	3.03e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—breast cancer	1.18e-06	3e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1A—breast cancer	1.18e-06	2.99e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—breast cancer	1.18e-06	2.99e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTEN—breast cancer	1.17e-06	2.98e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HRAS—breast cancer	1.17e-06	2.97e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ABCB1—breast cancer	1.17e-06	2.96e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—breast cancer	1.16e-06	2.95e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MAPK3—breast cancer	1.15e-06	2.93e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HRAS—breast cancer	1.15e-06	2.93e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK8—breast cancer	1.15e-06	2.92e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1B—breast cancer	1.15e-06	2.92e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TYMS—breast cancer	1.15e-06	2.91e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—breast cancer	1.15e-06	2.91e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—breast cancer	1.14e-06	2.88e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—BRAF—breast cancer	1.13e-06	2.88e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1B—breast cancer	1.13e-06	2.88e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTM1—breast cancer	1.13e-06	2.88e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NCOR1—breast cancer	1.13e-06	2.88e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PLA2G4A—breast cancer	1.13e-06	2.88e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP3—breast cancer	1.12e-06	2.86e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2—breast cancer	1.12e-06	2.85e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CA—breast cancer	1.12e-06	2.85e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—breast cancer	1.12e-06	2.85e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—breast cancer	1.12e-06	2.84e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP3—breast cancer	1.11e-06	2.82e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2—breast cancer	1.11e-06	2.82e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1—breast cancer	1.1e-06	2.8e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—breast cancer	1.1e-06	2.8e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT2—breast cancer	1.1e-06	2.8e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—breast cancer	1.1e-06	2.79e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—breast cancer	1.09e-06	2.78e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JUN—breast cancer	1.09e-06	2.78e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SRC—breast cancer	1.09e-06	2.77e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—breast cancer	1.09e-06	2.76e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CTNNB1—breast cancer	1.08e-06	2.75e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GPX1—breast cancer	1.08e-06	2.75e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—breast cancer	1.08e-06	2.74e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JUN—breast cancer	1.08e-06	2.74e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP1A1—breast cancer	1.07e-06	2.73e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CTNNB1—breast cancer	1.07e-06	2.72e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ERCC2—breast cancer	1.06e-06	2.7e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—breast cancer	1.06e-06	2.7e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—breast cancer	1.06e-06	2.69e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CD—breast cancer	1.06e-06	2.69e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1A—breast cancer	1.06e-06	2.69e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTEN—breast cancer	1.06e-06	2.68e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STAT3—breast cancer	1.05e-06	2.67e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CA—breast cancer	1.05e-06	2.67e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—breast cancer	1.05e-06	2.66e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SERPINE1—breast cancer	1.05e-06	2.66e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1A—breast cancer	1.04e-06	2.66e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTEN—breast cancer	1.04e-06	2.65e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HRAS—breast cancer	1.04e-06	2.64e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—breast cancer	1.04e-06	2.63e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK8—breast cancer	1.03e-06	2.63e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—breast cancer	1.03e-06	2.62e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK8—breast cancer	1.02e-06	2.59e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—breast cancer	1.02e-06	2.58e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK3—breast cancer	1e-06	2.55e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MTHFR—breast cancer	1e-06	2.54e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOS3—breast cancer	1e-06	2.54e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—breast cancer	9.94e-07	2.52e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SRC—breast cancer	9.8e-07	2.49e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—breast cancer	9.75e-07	2.48e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TGFB1—breast cancer	9.73e-07	2.47e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SRC—breast cancer	9.67e-07	2.46e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—breast cancer	9.54e-07	2.43e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—breast cancer	9.54e-07	2.42e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CA—breast cancer	9.53e-07	2.42e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MDM2—breast cancer	9.49e-07	2.41e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RAF1—breast cancer	9.46e-07	2.4e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STAT3—breast cancer	9.45e-07	2.4e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—breast cancer	9.42e-07	2.39e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RELA—breast cancer	9.41e-07	2.39e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB2—breast cancer	9.36e-07	2.38e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STAT3—breast cancer	9.32e-07	2.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CB—breast cancer	9.23e-07	2.35e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MTOR—breast cancer	9.23e-07	2.35e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CAV1—breast cancer	9.23e-07	2.34e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—breast cancer	9.17e-07	2.33e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK3—breast cancer	9.03e-07	2.29e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—breast cancer	9.01e-07	2.29e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK3—breast cancer	8.91e-07	2.26e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—breast cancer	8.87e-07	2.25e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HRAS—breast cancer	8.81e-07	2.24e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—breast cancer	8.78e-07	2.23e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TGFB1—breast cancer	8.76e-07	2.23e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1B—breast cancer	8.66e-07	2.2e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—breast cancer	8.66e-07	2.2e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TGFB1—breast cancer	8.64e-07	2.2e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—breast cancer	8.59e-07	2.18e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—breast cancer	8.57e-07	2.18e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP3—breast cancer	8.49e-07	2.16e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2—breast cancer	8.48e-07	2.15e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—breast cancer	8.47e-07	2.15e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—breast cancer	8.44e-07	2.14e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CG—breast cancer	8.41e-07	2.14e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CA—breast cancer	8.28e-07	2.1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—breast cancer	8.27e-07	2.1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JUN—breast cancer	8.25e-07	2.1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CTNNB1—breast cancer	8.19e-07	2.08e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—breast cancer	8.11e-07	2.06e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—breast cancer	8.02e-07	2.04e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—breast cancer	8.01e-07	2.04e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—breast cancer	8.01e-07	2.03e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1A—breast cancer	8e-07	2.03e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTEN—breast cancer	7.98e-07	2.03e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK8—breast cancer	7.8e-07	1.98e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—breast cancer	7.78e-07	1.98e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HRAS—breast cancer	7.66e-07	1.95e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CA—breast cancer	7.45e-07	1.89e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SRC—breast cancer	7.4e-07	1.88e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CD—breast cancer	7.39e-07	1.88e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CA—breast cancer	7.36e-07	1.87e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—breast cancer	7.33e-07	1.86e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALB—breast cancer	7.29e-07	1.85e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—breast cancer	7.21e-07	1.83e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—breast cancer	7.21e-07	1.83e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT3—breast cancer	7.14e-07	1.81e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—breast cancer	7.12e-07	1.81e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NOS3—breast cancer	6.98e-07	1.77e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HRAS—breast cancer	6.9e-07	1.75e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK3—breast cancer	6.82e-07	1.73e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HRAS—breast cancer	6.81e-07	1.73e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—breast cancer	6.76e-07	1.72e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—breast cancer	6.63e-07	1.68e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFB1—breast cancer	6.61e-07	1.68e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—breast cancer	6.6e-07	1.68e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—breast cancer	6.51e-07	1.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—breast cancer	6.48e-07	1.65e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CB—breast cancer	6.44e-07	1.64e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—breast cancer	6.38e-07	1.62e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—breast cancer	6.13e-07	1.56e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—breast cancer	6.09e-07	1.55e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—breast cancer	6.01e-07	1.53e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CA—breast cancer	5.63e-07	1.43e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTEN—breast cancer	5.57e-07	1.41e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—breast cancer	5.44e-07	1.38e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRAS—breast cancer	5.21e-07	1.32e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—breast cancer	4.98e-07	1.27e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—breast cancer	4.6e-07	1.17e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CA—breast cancer	3.93e-07	9.98e-06	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—breast cancer	3.21e-07	8.15e-06	CbGpPWpGaD
